These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12060497)

  • 1. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
    Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
    J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node ratio: a new feature for defining risk category of node-positive breast cancer patients.
    Yang C; Liu F; Li S; Li W; Zhai L; Ren M; Li Y; Lang R; Fan Y; Zhang X; Fu L
    Int J Surg Pathol; 2012 Dec; 20(6):546-54. PubMed ID: 22736300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
    Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
    Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor infiltrating regulatory T cells in human breast cancer and associated draining lymph nodes: an in-situ analysis].
    Wang HY; Shi QF; Sun Y; He JJ; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):95-100. PubMed ID: 23710915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance Between FISH Analysis of Her-2/Neu Gene in Breast Duct Carcinoma and Corresponding Axillary Nodal Metastases: Egyptian National Cancer Institute Experience.
    Badawy OM; Hassan H; ELBakey HA; Mosaad M
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):295-300. PubMed ID: 29750667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
    Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
    Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of computed tomography perfusion in assessing metastatic involvement of enlarged axillary lymph nodes in patients with breast cancer.
    Liu Y; Bellomi M; Gatti G; Ping X
    Breast Cancer Res; 2007; 9(4):R40. PubMed ID: 17615058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
    Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
    Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
    Knutson KL; Disis ML
    Clin Exp Immunol; 2004 Feb; 135(2):322-9. PubMed ID: 14738463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon production in lymph nodes draining breast carcinoma and its augmentation by OK-432].
    Nakajima Y; Akimoto M; Kimura M; Matano S; Hirakawa H; Kasai M
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2766-71. PubMed ID: 2428312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
    Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
    Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.